Replies to post #144972 on Biotech Values

[DewDiligence]

Re: M402 ASCO data

Thanks, ghmm—now that the M402 ASCO poster is back online, let me repeat my reply in #msg-76501405 to iwfal’s post in #msg-76500997 (and to biomaven’s nearly identical post in #msg-77151800):

I think it’s a little early to say that M402 will have a poor response rate in phase-1/2 trials. In the Capan-2 mouse experiment reported in the ASCO poster, M402 reduced primary tumor weight to a fairly impressive degree when given as either monotherapy or in combination with Gemzar.